NASDAQ · ARAY

Accuray Incorporated

Healthcare · Medical - Devices

$0.24▲ 3.43% ($0.01)at close

After hours$0.24▼ 1.99%7:30 PM ET

52-week

$0.22$2.10

Market cap

No multiple

What the market price implies · Reverse DCF

Historical revenue grew by -1.67%/yr over the past 4 years.

Selected forecast · Base scenario

0.8%/yr · actual 10-year annualized revenue growth

Year 1 growth: 0%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.24

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.

Year 1 growth 0% · Ending margin 0% · Discount rate 13.96%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 17, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 18, 2026, 1:20 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -85.23%Revenue (TTM): -12.34%FCF (TTM): -179.38%

What changed

The stock fell 85.23% over the last year. Revenue declined 12.34% over the trailing twelve months. Operating margin moved from 1.71% to -6.58%. Free cash flow declined 179.38% over the trailing twelve months.

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Operating margin stands at -6.58%. Revenue declined 12.34% — this read reverses if that trend stabilizes. Free cash flow fell 179.38% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.

Performance

Return analysis

Company profile

Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors.

CEOStephen R. LaNeve

SectorHealthcare

IndustryMedical - Devices

Employees809

IPO dateFeb 8, 2007

https://www.accuray.com

Market multiples

Forward P/E—

EV/EBITDA-12.15

Enterprise value$174.26M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth-20.87%

Gross margin (FY2026)27.73%▼4.3ppvs FY2025

Operating margin (FY2026)-6.58%▼8.3ppvs FY2025

ROE-80.08%▼77.6ppYoY

Analyst consensus

RatingBuy

Target price$2.00▲729.88%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 4, 2026

Q4 FY26 · EPS est -$0.07 · Revenue est $95.8M

View